Intercept Pharma (ICPT) Tops Q2 EPS by 88c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Intercept Pharma (ICPT) Tops Q2 EPS by 88c

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

July 29, 2021 7:00 AM EDT

Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter

Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million

Updates to the Ocaliva U.S. Prescribing Information complete

Company provides regulatory update on NASH fibrosis program in the U.S.

Company to host conference call today at 8:30 a.m. ET

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.... More